Full Members

 

DIRECTOR

Dr. Silvia Vidal

Silvia Vidal, PhD, is a Professor, Department of Human Genetics, McGill University and an Associate Member of the Department of Microbiology and Immunology, and is Director of the CTG. She holds a Tier 1 Canada Research Chair in Host Responses to Virus Infections and is the recipient of the Premier’s Research Excellence Award. She uses mouse genetic platforms to discover and functionally characterize the molecular interface between pathogenic viruses, inflammation and immunity. Her laboratory made inroads in characterizing mechanisms of self/non-self discrimination by NK cells during viral infection and pathways that control inflammatory responses during coxsackieviral myocarditis and influenza pneumonia. She has also developed an internationally recognized program in ENU mutagenesis and infectious diseases. Vidal’s program has spearheaded a number of projects and collaborations with academia and industry at McGill and abroad on gene discovery in human infectious and inflammatory disorders.

Co-Director

Dr. Philippe Gros

Philippe Gros, PhD, Vice-Dean, Life Sciences, Faculty of Medicine, McGill University.  Dr. Gros is a James McGill Professor of the Department of Biochemistry, and founding member of the CTG. He is also a member of the McGill International Center for Tuberculosis, and the Goodman Cancer Research Center, and is an associate member of the Departments of Human Genetics, and Microbiology and Immunology. His main area of investigation concerns the genetic analysis of susceptibility to infections, pre-disposition to neural tube defects, and models of carcinogen-induced cancer. He has received several prestigious awards since 2008 including, the Wilder Penfield Prize (Gouvernement du Québec; 2008), the Killam Prize in Health Sciences (Canada Council of the Arts; 2008), the Champion of Genetics Awards (GeneCure Foundation; 2011), the Queen Elizabeth II Diamond Jubilee Medal (Association of Universities and Colleges of Canada, 2013), and the McLaughlin Medal (Royal Society of Canada, 2014).  He acts as an advisor for several organizations, including the Burroughs Wellcome Fund and the Canadian Institutes of Health Research and the Bill and Melinda Gates Foundation. His experience in the biotechnology sector, includes the co-founding of PhageTech, and Emerillon Therapeutics (Xenon).